MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$5,534,069
(16.90%↑ Y/Y)
Gross product revenue
$4,878,720
Loss before income
taxes
-$5,269,829
(17.59%↑ Y/Y)
Income tax expense
$264,240
(0.00%↑ Y/Y)
Revenue
$3,944,111
Gross-to-net adjustments
$934,609
Operating loss
-$5,252,276
Total other income
(expense), net
-$17,553
Gross profit
$3,154,903
Interest income
$28,288
Cost of revenues
$789,208
Total operating
expenses
$8,407,179
(31.47%↑ Y/Y)
Interest expense
$45,841
Stock-based compensation
general and...
$3,956,050
(118.75%↑ Y/Y)
General and
administrative
$2,859,339
(-13.93%↓ Y/Y)
Research and development
$1,018,352
(-19.47%↓ Y/Y)
Amortization of in-process
research and development
$573,438
Back
Back
Income Statement
source: myfinsight.com
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)